International experience of using olaparib for metastatic castration-resistant prostate cancer: literature review

被引：0
|
作者：
Matveev, V. B. [1 ]
Khalmurzaev, O. A. [1 ]
Evsyukova, O., I [1 ]
机构：
[1] Minist Hlth Russia, NN Blokhin Natl Med Res Ctr Oncol, 24 Kashirskoe Shosse, Moscow 115478, Russia
来源：
ONKOUROLOGIYA | 2020年 / 16卷 / 04期
关键词：
prostate cancer; HRR mutations; BRCA; olaparib; DNA-REPAIR;
D O I：
10.17650/1726-9776-2020-16-4-197-206
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The following review presents a problem of metastatic castration-resistant prostate cancer and its association with germline or somatic mutations in homologous recombination repair (HRR). In 2020, olaparib was approved in the Russian Federation as a monotherapy for metastatic castration-resistant prostate cancer with germline or somatic mutations of genes involved in DNA repair by homologous recombination, after progression on therapy with new hormonal drugs. We describe a review of the main olaparib clinical trials assessing its efficacy, safety and tolerance in metastatic castration-resistant prostate cancer patients.
引用
收藏
页码：197 / 206
页数：10
相关论文
共 50 条
  • [1] Olaparib in Metastatic Castration-Resistant Prostate Cancer
    Smith, Thomas J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (12): : 1175 - 1175
  • [2] Olaparib in metastatic castration-resistant Prostate Cancer
    Lorenz, Judith
    AKTUELLE UROLOGIE, 2022, 53 (02)
  • [3] Olaparib for Metastatic Castration-Resistant Prostate Cancer
    de Bono, J.
    Mateo, J.
    Fizazi, K.
    Saad, F.
    Shore, N.
    Sandhu, S.
    Chi, K. N.
    Sartor, O.
    Agarwal, N.
    Olmos, D.
    Thiery-Vuillemin, A.
    Twardowski, P.
    Mehra, N.
    Goessl, C.
    Kang, J.
    Burgents, J.
    Wu, W.
    Kohlmann, A.
    Adelman, C. A.
    Hussain, M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (22): : 2091 - 2102
  • [4] Olaparib for Metastatic Castration-Resistant Prostate Cancer
    Mutetwa, Tinaye
    Foulkes, William D.
    Polak, Paz
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (09): : 890 - 890
  • [5] Re: Olaparib for Metastatic Castration-resistant Prostate Cancer
    Cumberbatch, Marcus
    Condon, Benjamin
    Lawrentschuk, Nathan
    Murphy, Declan G.
    EUROPEAN UROLOGY, 2021, 79 (02) : 319 - 320
  • [6] Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
    Hussain, Maha
    Mateo, Joaquin
    Fizazi, Karim
    Saad, Fred
    Shore, Neal
    Sandhu, Shahneen
    Chi, Kim N.
    Sartor, Oliver
    Agarwal, Neeraj
    Olmos, David
    Thiery-Vuillemin, Antoine
    Twardowski, Przemyslaw
    Roubaud, Guilhem
    Ozguroglu, Mustafa
    Kang, Jinyu
    Burgents, Joseph
    Gresty, Christopher
    Corcoran, Claire
    Adelman, Carrie A.
    de Bono, Johann
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (24): : 2345 - 2357
  • [7] Re: Olaparib for Metastatic Castration-resistant Prostate Cancer
    Di Lorenzo, Giuseppe
    Autorino, Riccardo
    EUROPEAN UROLOGY, 2020, 78 (05) : 767 - 768
  • [8] Re: Olaparib for Metastatic Castration-Resistant Prostate Cancer
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2020, 204 (04): : 877 - 878
  • [9] Olaparib for Metastatic Castration-Resistant Prostate Cancer REPLY
    de Bono, Johann
    Kang, Jinyu
    Hussain, Maha
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (09): : 891 - 891
  • [10] Re: Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2021, 206 (01): : 158 - 159
12345